ML-004 (IR)/(ER) tablet + ML-004 Placebo
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Autism Spectrum Disorder
Conditions
Autism Spectrum Disorder
Trial Timeline
Sep 13, 2022 → Nov 1, 2026
NCT ID
NCT05081245About ML-004 (IR)/(ER) tablet + ML-004 Placebo
ML-004 (IR)/(ER) tablet + ML-004 Placebo is a phase 2 stage product being developed by MapLight Therapeutics for Autism Spectrum Disorder. The current trial status is active. This product is registered under clinical trial identifier NCT05081245. Target conditions include Autism Spectrum Disorder.
What happened to similar drugs?
0 of 10 similar drugs in Autism Spectrum Disorder were approved
Approved (0) Terminated (2) Active (8)
Hype Score Breakdown
Clinical
12
Activity
12
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05081245 | Phase 2 | Active |
Competing Products
20 competing products in Autism Spectrum Disorder